HALO beat EPS expectations by 6.64%
Feb 18, 2025, 11:32 PM
0.00%
What does HALO do
Halozyme Therapeutics, a San Diego-based biopharmaceutical company, specializes in drug delivery technology and has two proprietary products, Hylenex and XYOSTED, focusing on subcutaneous administration. Founded in 2003, it employs 373 people and partners with other firms for drug-device combinations.
Halozyme Therapeutics (HALO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Halozyme Therapeutics's actual EPS was $1.26, beating the estimate of $1.18 per share, resulting in a 6.64% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.